No Data
Radiopharm Theranostics Is Maintained at Buy by B. Riley Securities
Radiopharm Theranostics Analyst Ratings
Australia's Agency Has Approved Radiopharm Theranostics' First-in-human Phase 1 Trial Of Rad 402, For Metastatic Or Locally Advanced Prostate Cancer-6K
Radiopharm Theranostics Limited: Strategic Advancements and Financial Stability Support Buy Rating
Radioligand Therapy (RLT) Market Worth US$10.9 Billion by 2035 With 13.2% CAGR | MarketsandMarkets
Radiopharm Theranostics Limited - Special Call